Biosense

The year was 1997 when the exciting news broke. Johnson & Johnson, ranked 39th on the Fortune 500, would make its first entry into the Israeli market with a $427 million purchase of Biosense. This shattered the then-record for Israeli exits, and came more than a decade before the tiny country would be labeled the “Start-up Nation”. Yet, none of this would be possible if Biosense did not fiercely claim and defend their burgeoning patent portfolio. In doing so, they retained the preeminent local firm for IP protection – Kligler & Associates.